POLI HARLOWE, MARIA CECILIA BERTA
Preferred name
POLI HARLOWE, MARIA CECILIA BERTA
Main Affiliation
Email
mpoli@alemana.cl
ORCID
0000-0001-6817-0573
Scopus Author ID
57214078113
64 results
Now showing 1 - 10 of 64
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Increased risk of long-term post-COVID neurologic symptoms in women(2023); ; ; Catalina Arbat8 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19(2022)Scopus© Citations 204 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genomic Characterization of a Pediatric Cohort with Lymphoproliferative Disorders(2020); 1 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 15 - Some of the metrics are blocked by yourconsent settings
Item type:Product, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome(2018); 1Scopus© Citations 142 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab(2020); ; Lorena I. Tapia<jats:p>We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction, including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure, and gastrointestinal involvement characterized by inflammation of the wall of the bowel and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical improvement and normalization of inflammatory markers. PIMS-TS is a new disease developed in a small percentage of patients, so a high degree of suspicion is necessary to establish the diagnosis. Supportive care is of paramount importance. The use of Tocilizumab to control the inflammatory response is likely to be beneficial, but the best immunotherapeutic agent has not yet been established. Randomized clinical studies should be run to determine the best treatment.</jats:p>14Scopus© Citations 20 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Partial loss of function mutations in GINS4 lead to natural killer cell deficiency with neutropenia(2022)3 - Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - TGFβ links EBV to multisystem inflammatory syndrome in children(Molecular Signatures Database (MSigDB), 2025); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Parámetros hematológicos y biomarcadores predictores de gravedad en Síndrome Inflamatorio Pediátrico Multisistémico asociado a SARS-CoV-2(2021)20Scopus© Citations 10